ABSTRACT
Five years have passed since this chapter was published in the last edition of this book; in this short time, there has been a remarkable expansion in the amount of clinical data on the use of botulinum toxins for cosmetic purposes. Two of the biggest milestones since the last edition have been the approval by the U.S. Food and Drug Administration (FDA) of botulinum toxin type A (BTX-A; BOTOX1) for the treatment of glabellar lines, and the introduction into clinical use of an additional neurotoxin alternative-botulinum toxin type B (BTX-B, MYOBLOC). In addition, the use of cosmetic BTX has moved beyond simple clinical efficacy to what is now called an art, shaping and sculpting the face into more pleasing contours without scalpel or other invasive procedures.
